CVS Health (NYSE:CVS) Releases FY 2025 Earnings Guidance

CVS Health (NYSE:CVS) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.600-6.700 for the period, compared to the consensus estimate of 6.610. The company issued revenue guidance of $400.0 billion-$400.0 billion, compared to the consensus revenue estimate of $399.0 billion.

CVS Health Trading Down 0.4%

Shares of CVS stock opened at $77.95 on Thursday. CVS Health has a fifty-two week low of $43.56 and a fifty-two week high of $85.15. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.63 and a current ratio of 0.83. The stock’s fifty day moving average is $79.08 and its two-hundred day moving average is $72.24. The firm has a market capitalization of $98.95 billion, a P/E ratio of 205.14, a PEG ratio of 0.77 and a beta of 0.48.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Research analysts expect that CVS Health will post 5.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CVS shares. UBS Group restated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Argus boosted their price objective on CVS Health from $80.00 to $91.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Mizuho lifted their price target on CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Zacks Research lowered shares of CVS Health from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $94.67.

Hedge Funds Weigh In On CVS Health

Several large investors have recently made changes to their positions in the stock. Legacy Advisors LLC acquired a new stake in CVS Health during the 3rd quarter worth approximately $249,000. Resurgent Financial Advisors LLC purchased a new stake in shares of CVS Health during the third quarter worth $215,000. PFG Advisors acquired a new stake in shares of CVS Health in the third quarter valued at $205,000. MUFG Securities EMEA plc acquired a new position in CVS Health during the 2nd quarter worth $258,000. Finally, McIlrath & Eck LLC increased its holdings in CVS Health by 422.9% during the 2nd quarter. McIlrath & Eck LLC now owns 3,383 shares of the pharmacy operator’s stock worth $233,000 after purchasing an additional 2,736 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.